BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 25858641)

  • 1. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
    Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
    Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
    Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
    J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
    Tomcik M; Zerr P; Pitkowski J; Palumbo-Zerr K; Avouac J; Distler O; Becvar R; Senolt L; Schett G; Distler JH
    Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.
    Reich N; Tomcik M; Zerr P; Lang V; Dees C; Avouac J; Palumbo K; Horn A; Akhmetshina A; Beyer C; Xie W; Bennett BL; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
    Beyer C; Reich N; Schindler SC; Akhmetshina A; Dees C; Tomcik M; Hirth-Dietrich C; von Degenfeld G; Sandner P; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 Jun; 71(6):1019-26. PubMed ID: 22294631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
    Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
    Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis.
    Zhang Y; Zhu H; Layritz F; Luo H; Wohlfahrt T; Chen CW; Soare A; Bergmann C; Ramming A; Groeber F; Reuter C; Fornasini G; Soukhareva N; Schreiber B; Ramamurthy S; Amann K; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Aug; 72(8):1385-1395. PubMed ID: 32182396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.
    Zhang Y; Dees C; Beyer C; Lin NY; Distler A; Zerr P; Palumbo K; Susok L; Kreuter A; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2015 May; 74(5):936-43. PubMed ID: 24431397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation.
    Zhu L; Song Y; Li M
    J Dermatol Sci; 2015 Jan; 77(1):63-70. PubMed ID: 25465161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis.
    Skhirtladze C; Distler O; Dees C; Akhmetshina A; Busch N; Venalis P; Zwerina J; Spriewald B; Pileckyte M; Schett G; Distler JH
    Arthritis Rheum; 2008 May; 58(5):1475-84. PubMed ID: 18438865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D receptor regulates TGF-β signalling in systemic sclerosis.
    Zerr P; Vollath S; Palumbo-Zerr K; Tomcik M; Huang J; Distler A; Beyer C; Dees C; Gela K; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2015 Mar; 74(3):e20. PubMed ID: 24448349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
    Dees C; Beyer C; Distler A; Soare A; Zhang Y; Palumbo-Zerr K; Distler O; Schett G; Sandner P; Distler JH
    Ann Rheum Dis; 2015 Aug; 74(8):1621-5. PubMed ID: 25817717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.